Bd receives fda 510(k) clearance for first-of-its-kind high-throughput diagnostic test for infectious vaginitis

Bd vaginal panel on bd cor™ system tests for multiple common types of vaginitis using only one swab, one test franklin lakes, n.j. , march 16, 2023 /prnewswire/ -- bd (becton, dickinson and company) (nyse: bdx), a leading global medical technology company, today announced that it has received 510(k) clearance from the u.s. food and drug administration (fda) for the bd vaginal panel on the bd cor™ system, a comprehensive diagnostic test that directly detects the three most common infectious causes of vaginitis using bd's high-throughput molecular diagnostic platform for large laboratories.
BDX Ratings Summary
BDX Quant Ranking